At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
In Brief
A Phase 2 clinical trial evaluating Deferoxamine and Normal saline for Acute Kidney Injury. Active but no longer recruiting, targeting 320 participants across 3 sites.
Signals
Detailed Summary
Multiple lines of evidence support a central role of iron in causing acute kidney injury (AKI), including the finding that prophylactic administration of iron chelators attenuates AKI in animal models. Patients undergoing cardiac surgery may be particularly susceptible to iron-mediated kidney injury due to the profound hemolysis that often occurs from cardiopulmonary bypass. The investigators will test in a phase 2, randomized, double-blind, placebo-controlled trial whether prophylactic administration of deferoxamine decreases the incidence of AKI following cardiac surgery.
Study Details
Timeline
Arms & Interventions
Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
Normal saline (240mL) intravenous infusion over 12 hours
Interventions
Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
Normal saline (240mL) intravenous infusion over 12 hours